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background: GDF-15, high sensitivity troponin-I (hs-TnI) and NT-proBNP levels predict cardiovascular events in healthy elderly subjects, and 
in patients with acute coronary syndrome and heart failure. Hs-TnI and NT-proBNP are also prognostic in atrial fibrillation (AF). We evaluated the 
prognostic value of GDF-15 in addition to hs-TnI and NT-proBNP during treatment with apixaban or warfarin in patients with AF in the ARISTOTLE trial.
methods: Biomarkers were measured at randomization in 14,798 patients. Efficacy and safety outcomes were compared across quartiles of GDF-
15 adjusted for baseline characteristics, other biomarkers and randomized treatment. Treatment effects were compared across GDF-15 quartiles.
results: There were continuous positive relationships between the GDF-15 level and stroke, mortality and major bleeding. The prognostic value of 
GDF-15 was independent of clinical characteristics and the CHA2DS2VASc score. Adjusting for biomarkers attenuated the prognostic value of GDF-
15 for stroke while death and major bleeding remained (Table). Apixaban consistently reduced stroke, mortality and bleeding, regardless of GDF-15 
levels (p > 0.10).
conclusions: GDF-15 is an independent risk indicator for stroke, death and major bleeding in AF. The prognostic value for bleeding and death 
remained after adjusting for hs-TnI and NT-proBNP. The benefits of apixaban over warfarin were consistent regardless of GDF-15 level.
Table. Outcomes in relation to quartiles of GDF-15
Outcome
GDF-15
(ng/L)
n
Events
(%/yr)
HR (95% CI)
adjusted for base-line characteristics
p-value
HR (95% CI)
adjusted also for TnI & NT-
proBNP
p-value
Stroke/SEE
<=977 3705 67 (0.90) Reference . .
>977-1383 3697 86 (1.21) 1.14 (0.82-1.58) . 1.04 (0.75-1.45) .
>1383 - 2052 3699 109 (1.58) 1.36 (0.98-1.88) . 1.20 (0.86-1.68) .
>2052 3697 134 (2.03) 1.66 (1.20-2.31) 0.0111 1.35 (0.94-1.94) 0.3161
Major bleed
<=977 3698 85 (1.22) Reference . .
>977-1383 3691 132 (2.01) 1.34 (1.02-1.77) . 1.28 (0.96-1.69) .
>1383 - 2052 3694 190 (3.05) 1.83 (1.40-2.39) . 1.64 (1.24-2.16) .
>2052 3684 262 (4.53) 2.45 (1.87-3.21) <0.0001 1.98 (1.47-2.66) <0.0001
Death
<=977 3705 102 (1.34) Reference . .
>977-1383 3697 185 (2.54) 1.72 (1.35-2.21) . 1.50 (1.17-1.93) .
>1383 - 2052 3699 286 (4.04) 2.40 (1.89-3.04) . 1.85 (1.44-2.37) .
>2052 3697 488 (7.19) 3.53 (2.79-4.47) <0.0001 2.09 (1.62-2.71) <0.0001
